Form 4: Seres Therapeutics Director Claire Fraser Granted Stock Options

Director Claire Fraser of Seres Therapeutics, Inc. [MCRB] was granted stock options to purchase 100,000 shares of common stock at an exercise price of $0.58 on April 10, 2025.

Summary

• On April 10, 2025, Claire Fraser, a director of Seres Therapeutics, Inc. [MCRB], was granted stock options.
• The options allow Fraser to purchase 100,000 shares of Seres Therapeutics common stock at an exercise price of $0.58 per share.
• The options vest in full on the earlier of April 10, 2026, or the day immediately prior to the company's 2026 annual meeting of shareholders.
• The options expire on April 9, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative performance, but rather aligns the director's interests with the company's.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Moderna, BioNTech, and Gilead Sciences also utilize stock options to incentivize their leadership teams.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The granting of stock options could have a slightly dilutive effect on existing shareholders, but it also incentivizes the director to work towards increasing shareholder value.

Key Dates

Keywords

Seres Therapeutics, MCRB, stock options, director, Claire Fraser, beneficial ownership, Form 4, equity securities